display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR positivela/mBC - HR positive - L2 - all population
chemotherapy
non platinum-based chemotherapy
microtubul inhibitor
eribulin NCT03051659
pegylated liposomal doxorubicin and cyclophosphamide ICON

Study type: